PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$33.66 USD
+2.48 (7.95%)
Updated May 15, 2024 04:00 PM ET
After-Market: $33.68 +0.02 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 81 - 100 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
NHS-England Delay Is Not Translarna Specific
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Program Advances, Triggering a $10M Milestone
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
3Q Corporate Update to Focus on Translarna
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Program Readthrough and Adjusting Estimates Post Financing
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Emerging Natural History Data Support Phase 3 Assumptions
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Small Molecules, Big Opportunities - Target to $58
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Ataluren Phase 3 Fully Enrolled, Accelerated Approval Could Be Next
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.